Covidien announces the availability of the technology

Monday, January 10, 2011

Covidien (Boulder) announced the availability of the new Infinity® MCable® with Nellcor™ OxiMax™ technology as an integrated component of the Dräger Infinity Acute Care System™ in Europe. This system includes the portable Infinity M540 monitor. The Infinity MCable with Nellcor OxiMax technology adds two vital features to the compact Dräger monitor: Nellcor OxiMax specialty pulse oximetry sensors and Nellcor SatSeconds™ alarm management technology.  

InDevR announces promising results

Monday, January 10, 2011

InDevR (Boulder) announced promising results from a blind study to test the effectiveness of the company’s ViroCyt™ Virus Counter® for virus quantification.  The results, published in the January issue of Journal of Virological Methods, “indicate that the Virus Counter provides a reliable means to quantify baculovirus samples... in a fraction of time required to conduct a plaque assay.” This method could streamline research and development efforts for vaccine manufacturers, pharmaceutical and biotechnology companies and researchers worldwide. 

Omni Bio announces that U.S. Patent

Monday, January 10, 2011

Omni Bio Pharmaceutical, Inc. (Greenwood Village) announced that U.S. Patent No. 7,850,970, entitled "Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections," was issued by the United States Patent and Trademark Office (USPTO) on December 14, 2010 (the "New Patent"). The New Patent is part of the technology licensed to Omni Bio through one of its technology license agreements with the University of Colorado Denver. The New Patent covers inhibition of all forms of Bacillus anthracis infection (commonly known as anthrax) using one or more of four new peptides made up of 10 linked amino acids.  

ARCA biopharma President panelist

Wednesday, January 05, 2011

ARCA biopharma, Inc. (Broomfield) announced that Dr. Michael Bristow, President and Chief Executive Officer was a featured panelist at the Personalized Medicine Coalition’s Conference, New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care, January 6, 2011 at the George Washington University.  Dr. Bristow spoke on “Development of New Treatments and Treatment Strategies for Heart Failure.”  

Array CEO at J.P. Morgan Healthcare Conference

Tuesday, January 04, 2011

Array BioPharma Inc. (Boulder) announced that its Chief Executive Officer, Robert E. Conway, will speak at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 12. 

Pico-Tesla announces expanded Phase III clinical trial

Tuesday, January 04, 2011

Pico-Tesla (Littleton) announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa. In addition, Pico-Tesla announced that enrollment is approaching 50% of the patients required for this pivotal clinical trial.  The purpose of the ongoing Phase III pivotal clinical trial is to demonstrate the efficacy of Magneceutical® Therapy as an adjunctive therapy to improving aspects of health and quality of life that are relevant to patients with Parkinson's disease.  

The National Cancer Institute (NCI) announced the launch of a new pilot Regulatory Assistance Program

Monday, January 03, 2011

The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs announced the launch of a new pilot Regulatory Assistance Program. This first-ever NCI SBIR Regulatory Assistance Program is designed to aid NCI SBIR & STTR Phase II awardees in navigating the regulatory path.  The program is part of the NCI’s latest efforts to go beyond funding support and help small businesses bring innovative cancer products to market to ultimately help in the fight against cancer. This competitive program is open to NCI Phase II grantees and contractors with projects that are current, or have ended within the last two years.  Applications will be accepted and reviewed on an on-going basis until 5:00 pm EST, February 4, 2011.   Final selection of participants will be made by March 4, 2011.   

CBSA Logos

Sunday, January 02, 2011


Media Contact

Saturday, January 01, 2011

Primavera Group
Sheliah Reynolds, Senior Communications Strategist
Direct: 720-289-4739   

‘Fund of funds’ a top priority as Baumunk takes over CBSA

Sunday, July 18, 2010

Premium content from Denver Business Journal - by Greg Avery